Treatment of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

European Urology, Supplements

Volumn 6, Issue 14, 2007, Pages 800-808

  Hendricksen, Kees ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Chemotherapy; Intravesical therapy; Non muscle invasive; Novel therapeutics; Urothelial cell carcinoma

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APAZIQUONE; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; ISONIAZID; MITOMYCIN C; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER MUSCLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CHEMICAL CYSTITIS; CYSTECTOMY; CYSTITIS; DEVICE; DRUG ADMINISTRATION ROUTE; DRUG WITHDRAWAL; ELECTROMOTIVE DRUG ADMINISTRATION; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK; RISK ASSESSMENT; SKIN ALLERGY; STANDARD; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; UROTHELIAL CELL CARCINOMA;

EID: 34250821604     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.04.008     Document Type: Review

References (50)

1. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4-34
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
3. Oosterlinck W., Lobel B., Jakse G., Malmström P.-U., Stöckle M., and Sternberg C. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
4. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
5. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233-1238
6. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
7. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934-941
8. Gofrit O.N., Pode D., Lazar A., Katz R., and Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006) 303-307
9. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 (2005) 108-125
10. Kaasinen E., Rintala E., Hellström P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
11. Hendricksen K., Kiemeney L.A., Caris C., Janzing R., Witjes W., and Witjes J.A. Three schedules of adjuvant intravesical Epirubicin in patients with non-muscle invasive bladder cancer: a comparative study. Eur Urol Suppl 6 (2007) 60 (abstract no. 149)
12. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
13. Dutta S.C., Smith Jr. J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
14. Jakse G., Algaba F., Malmström P.-U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
15. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
16. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
17. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de B.C., and Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166 (2001) 476-481
18. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
19. van der Meijden A.P., Sylvester R.J., Oosterlinck W., Hoeltl W., and Bono A.V. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44 (2003) 429-434
20. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
21. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
22. Kiemeney L.A., Witjes J.A., Verbeek A.L., Heijbroek R.P., and Debruyne F.M. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 67 (1993) 806-812
23. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
24. Joudi F.N., Smith B.J., and O'donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
25. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888-893
26. Beretta G. Bladder cancer. In: Beretta G. (Ed). Mitomycin C (2001), Edizioni Minerva Medica, Turin 170-181
27. Onrust S.V., Wiseman L.R., and Goa K.L. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 15 (1999) 307-333
28. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1940
29. Witjes J.A., van der Heijden A.G., Vriesema J.L., Peters G.J., Laan A., and Schalken J.A. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45 (2004) 182-186
30. Laufer M., Ramalingam S., Schoenberg M.P., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21 (2003) 697-703
31. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
32. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20 (2002) 3193-3198
33. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729-2734
34. Palou J., Carcas A., Segarra J., et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 172 (2004) 485-488
35. Gardmark T., Carringer M., Beckman E., and Malmstrom P.U. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 66 (2005) 527-530
36. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66 (2005) 726-731
37. Walton M.I., Smith P.J., and Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase] in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3 (1991) 199-206
38. Li D., Gan Y., Wientjes M.G., Badalament R.A., and Au J.L. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 166 (2001) 2500-2505
39. van der Heijden A.G., Verhaegh G., Jansen C.F., Schalken J.A., and Witjes J.A. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173 (2005) 1375-1380
40. van der Heijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349-1353
41. Colombo R., Da Pozzo L.F., Lev A., Freschi M., Gallus G., and Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155 (1996) 1227-1232
42. Colombo R., Da Pozzo L.F., Salonia A., et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21 (2003) 4270-4276
43. Gofrit O.N., Shapiro A., Pode D., et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63 (2004) 466-471
44. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-72
45. Brausi M., Campo B., Pizzocaro G., et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51 (1998) 506-509
46. Colombo R., Brausi M., Da P.L., et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur Urol 39 (2001) 95-100
47. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170 (2003) 777-782
48. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51
49. Waidelich R., Stepp H., Baumgartner R., Weninger E., Hofstetter A., and Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165 (2001) 1904-1907
50. Berger A.P., Steiner H., Stenzl A., Akkad T., Bartsch G., and Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61 (2003) 338-341